Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to 145.46%.

  • Spero Therapeutics' EBITDA Margin fell 74200.0% to 145.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 115.46%, marking a year-over-year decrease of 1150400.0%. This contributed to the annual value of 152.91% for FY2024, which is 1748800.0% down from last year.
  • Latest data reveals that Spero Therapeutics reported EBITDA Margin of 145.46% as of Q3 2025, which was down 74200.0% from 17.22% recorded in Q2 2025.
  • In the past 5 years, Spero Therapeutics' EBITDA Margin ranged from a high of 735.02% in Q3 2021 and a low of 1586.9% during Q1 2022
  • Moreover, its 5-year median value for EBITDA Margin was 186.93% (2024), whereas its average is 337.61%.
  • Over the last 5 years, Spero Therapeutics' EBITDA Margin had its largest YoY gain of 12726100bps in 2022, and its largest YoY loss of -13208900bps in 2022.
  • Over the past 5 years, Spero Therapeutics' EBITDA Margin (Quarter) stood at 1065.6% in 2021, then skyrocketed by 119bps to 207.01% in 2022, then plummeted by -66bps to 69.63% in 2023, then tumbled by -307bps to 144.41% in 2024, then dropped by -1bps to 145.46% in 2025.
  • Its EBITDA Margin stands at 145.46% for Q3 2025, versus 17.22% for Q2 2025 and 250.78% for Q1 2025.